Skip to main content

Table 1 OS’s comparisons in recent studies

From: From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience

Study

Centre

Number of patients

Median age (years)

FIGO IB2 (%)

FIGO II (%)

FIGO III (%)

FIGO IV (%)

Pelvic LNI (%)

Lombo aortic LNI (%)

Median/Mean follow-up (months)

DFS % (CI 95%)

OS % (CI 95%)

DSS % (CI 95%)

Present study

Saint Etienne, France

94

63

10.6

73.3

16

0

34.1

0

43.9/54.3

56.7 (46.9–68.5)

61.9 (52.3–73.2)

68.5 (59.2–79.2)

Sturdza, [6]

International cohort

731

53

16.8

55.9

22.9

3.1

40.5

43

65

73

Touboul, [5]

Villejuif, France

150

47

32

61

7

0.7

32.7

0.7

−/43.2

66 (57–74)

71 (61–78)

Haie-Meder, [8]

Villejuif, France

84

46.5

23.8

44

26.2

6

36.9

53/−

57* (43–69)

52* (40–64)

Han, [21]

Toronto, Canada

7359

55 (mean)

8.2

52.5

35.8

3.5

40.8/−

58.2* (with brachytherapy), 46.2* (without)

64.3* (with brachytherapy), 51.5* (without)

Magne, [14]

Villejuif, France

113

76

3.5 (31% IA and IB1)

45,1

16,8

3.6

14.2

6.2

37.2/−

81** (72–88)

88.6** (77–92)

Gouy, [7]

Villejuif, France

237

46

33

55

10

2

21

30/−

71** (63–78)

78** (64–88)

Song, [28]

Chicago, US

113

49

19

57

24

0

17

0

26/−

58** (49–67)

66** (57–75)

74** (66–82)

Chargari, [37]

Villejuif, France

45

50

31.1

51

13.3

4.4

51.1

8.9

26/26.7

73***

78***

  1. Pathological lymph nodes were defined as lymph nodes > 1 cm in size, loss of oval shape on imaging, or positive on PET-CT imaging
  2. Survivals are given at 5-year, 4-year (*), 3-year (**) or 2-year (***)
  3. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, LNI lymph node involvement, DFS Disease-Free Survival, OS Overall Survival, DSS Disease-Specific Survival, PET-CT Positron Emission Tomography-Computed Tomography